Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We have some growing OEM opportunities as well, especially in our DRD segment and there are companies like mine Array and others that have been around a long time and very successful in growing double digit that have taken a bigger and bigger piece of our business and going direct with us |
| Momentum continued in our Biologics business as we experienced continued uptake of our Maurice Flex instrument and strong demand for consumables |
| [indiscernible] high value proposition is resonating with the translational research community, which is driving significant interest and rapid growth in its installed base |
| So our growth would have been better this quarter if there weren't for those timing issues that Kim talked about and so we do see a nice snapback in the diagnostics genomics submit going forward |
| Specifically, our GMP proteins business, ExoDx prostate and our Protein Simple franchise all delivered impressive growth in the quarter |
| Our portfolio remains incredibly well positioned in several high-growth and unpenetrated end markets, and our team will continue to leverage our strategic playbook and strong financial position to gain share, enter adjacent markets, introduce innovative products and solutions and capitalize on the tremendous opportunity in front of the company |
| Whatever the macro environment throws at us in the near term, our excellent management team and dedicated employees will continue to drive productivity to protect the bottom line, all while selectively investing in the growth pillars that will accelerate our overall company's growth rate when the market headwinds decide and turn back into tailwinds, and the winds will turn |
| During Kim's leadership of this segment, the team gained significant market acceptance and traction with the ExoDx prostate test, the revenue of our ASV business totaled the segment portfolio was strengthened through the Asuragen and Lunaphore acquisitions and multiple new product introductions and partnerships position the business for future growth |
| Obviously, had a really strong quarter from an organic growth standpoint |
| BaseScope and micro RNA scope increased almost 20% and 50%, respectively, and are experiencing increasing acceptance and traction in gene therapy applications |
| So we're super bullish on our Simple Western platform |
| Within the portfolio, we are experiencing continued momentum in base scope, which enables the detection of target sequences down to one nucleotide differences and microRNA scope for the visualization of microRNA and other nucleic acid targets |
| There's already been great evidence that we're going to have a strong future, I think, in Germany with him at the helm |
| We are proud of the innovative culture we have built as well as our commitment to corporate governance and operational integrity |
| We are very pleased with the traction Lunaphore is having with its comment launch, as Chuck highlighted initial integration efforts are progressing well |
| Europe had a very strong quarter as the region grew mid-teens overall, including particularly strong performance from our biopharma end market |
| That said, the European biopharma and academic end markets remain stable, and the new leadership team has maintained the positive momentum we experienced in the region over the last three quarters |
| Also, our spatial biology business delivered upper single-digit growth in the quarter with continued growth in RNA scope and strong performances in our BaseScope and microRNA product lines |
| Kim will be taking over an incredibly strong and talented team as well as a novel portfolio with leadership positions in some of the fastest-growing life science tools and diagnostic markets |
| That's going extremely well |
| As we highlighted during our recent Investor Day, our portfolio of proteomic research reagents, cell and gene therapy workflow solutions, analytical tools, spatial biology products and liquid biopsy diagnostics are aimed squarely at a $27 billion vessel market with amazing long-term growth prospects |
| However, our Exosome Diagnostics business remained very strong in the quarter as our fortified marketing message, strong clinical data and the updated Medicare LCD drove both test volume and revenue growth |
| And we're still showing growth right now, strong growth and double-digit growth in consumables |
| As we look at our relative performance to many of the life science companies that have reported so far this quarter, I'm especially proud of our team's execution and have even more confidence in the perseverance of our growth platforms |
| GMP proteins remains the cornerstone of our cell therapy offering and Bio-Techne continues to benefit from having the broadest menu available, including several proteins that are unique to Bio-Techne |
| We are as bullish as we have ever been on our long-term opportunities in China, but acknowledge that these headwinds will likely linger in the near term before improving |
| We've got strong IP |
| We also continue to gain traction with our portfolio of GMP small molecules |
| Jim and Will, I'm sure, are happy for Kim, but they're still here, and we're -- we've been a good team with very low politics for many years together |
| We are in the process of expanding our G&P portfolio to include additional media formulations, gene edit engineering capabilities and antibodies, positioning Bio-Techne to remain a leader in this rapidly growing industry |
| Statement |
|---|
| This region declined low teens during the quarter and underperformed our original expectations with the business climate deteriorating as the quarter progressed |
| As many of our life science tools peers have already mentioned, the macro environment in China continues to weaken, and the biopharma end market is softening, especially in the U.S |
| As a reminder, Europe was the region that was first experienced the effects of the post COVID slowdown, which contributed to a high single-digit decline in the comparable quarter of our last fiscal year |
| Moving on to the Diagnostics and Genomics segment operating margin at 0.7%, the segment's operating margin decreased compared to prior year's 12.4%, due primarily to the impact of the Lunaphore acquisition, and to a lesser extent, strategic growth investments as well as unfavorable product mix |
| The funding challenges we highlighted in the last earnings call persisted in the quarter, as Chinese government funding for life sciences R&D at hospitals and academic institutions is significantly lower than last year |
| A more challenging China funding and macro environment than expected represented an additional approximately 200 basis points headwind, while order timing in our Diagnostics and Genomics segment was another unanticipated headwind of approximately 100 basis points |
| So we just came back from China, and we are pretty much saying what everyone else is saying on their call this past week or -- this quarter was disappointing |
| Adjusted EPS was $0.41 compared to $0.45 in the prior year quarter, a decrease of 9% over last year |
| Adjusted operating margin for Q1 was 31.4%, a decrease of 340 basis points from the prior year period |
| This is a negative teens quarter coming off of a high teens quarter growth last quarter |
| The sources of these headwinds have remained relatively consistent during recent quarters, including a soft biotech funding environment, inventory destocking from a handful of our OEM customers, as well as broad economic challenges in one of our historically highest growing geographies, China |
| As Chuck previously mentioned, the soft biotech funding environment remained a drag on our North American business, while Europe saw strong growth but also had a less difficult comp as the region declined high single digits in the comparable quarter last year |
| Excluding the Lunaphore acquisition, which closed at the beginning of Q1, adjusted operating margin was 100 basis points lower than the prior year due to strategic investments, which was partially offset by diligent cost management |
| Additionally, private equity and VC funding activity has slowed in the geography, which is creating more cautious near-term spending patterns for cash-dependent biopharma companies in the region |
| So that's a much poorer performance than usual for us in the U.S |
| And to reiterate what I said earlier, in the near term, Protein Sciences can still be very challenged by China |
| That said, the timing of this recovery remains incrementally more challenging to call at this point |
| As Chuck previously mentioned, organic growth was negatively impacted by the timing of certain OEM and lab orders for our diagnostic controls and genetic testing products |
| The more cautious spending from our biotech customers, which we primarily experienced in the U.S |
| And so given that Bio-Techne has been under pressure for some time |
Please consider a small donation if you think this website provides you with relevant information